Trial Profile
Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Envafolimab (Primary)
- Indications Carcinoma; Colorectal cancer; Gastric cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors 3D Medicines
- 30 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
- 09 Mar 2022 Planned End Date changed from 1 Aug 2022 to 15 Dec 2025.
- 09 Mar 2022 Planned primary completion date changed from 12 Feb 2022 to 31 Dec 2023.